tradingkey.logo

Trinity Biotech PLC

TRIB
0.800USD
+0.092+13.06%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
15.41MMarktkapitalisierung
VerlustKGV TTM

Trinity Biotech PLC

0.800
+0.092+13.06%

mehr Informationen über Trinity Biotech PLC Unternehmen

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLC Informationen

BörsenkürzelTRIB
Name des UnternehmensTrinity Biotech PLC
IPO-datumOct 21, 1992
CEOGillard (John)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeOct 21
AddresseIda Business Park, Bray, Co Wicklow
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
Postleitzahl18
Telefon01135312955111
Websitehttps://www.trinitybiotech.com/
BörsenkürzelTRIB
IPO-datumOct 21, 1992
CEOGillard (John)

Führungskräfte von Trinity Biotech PLC

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
Nach RegionUSD
Name
Umsatz
Anteil
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

Aktionärsstatistik

Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Andere
29.87%
Aktionäre
Aktionäre
Anteil
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Andere
29.87%
Aktionärstypen
Aktionäre
Anteil
Corporation
60.60%
Hedge Fund
6.69%
Investment Advisor
5.47%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.46%
Andere
26.08%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
52
2.76M
62.28%
+305.43K
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
MiCo IVD Holdings, LLC
2.24M
60.6%
+1.79M
+400.00%
Dec 08, 2025
Renaissance Technologies LLC
171.36K
4.64%
+159.97K
+1404.10%
Sep 30, 2025
Hunter Associates Investment Management LLC
487.11K
13.19%
+399.53K
+456.18%
Sep 30, 2025
Citadel Advisors LLC
39.38K
1.07%
+39.38K
--
Sep 30, 2025
Two Sigma Investments, LP
36.23K
0.98%
+33.22K
+1101.76%
Sep 30, 2025
CAPTRUST Financial Advisors
27.25K
0.74%
+27.25K
--
Sep 30, 2025
Raymond James & Associates, Inc.
20.32K
0.55%
+15.25K
+300.77%
Sep 30, 2025
Williams & Novak Wealth Management, LLC
12.00K
0.32%
+7.60K
+172.73%
Sep 30, 2025
Becker Capital Management, Inc.
18.00K
0.49%
+14.40K
+400.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
16.64K
0.45%
+13.31K
+400.06%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Datum
Ex-Dividendentag
Art
Verhältnis
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
KeyAI